ReviewPharmaceutics2023
Nanosystems in Cardiovascular Medicine: Advancements, Applications, and Future Perspectives.
Review in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Targeted drug delivery systems for cardiovascular disease treatment: principles, targeting strategies, and future prospects.Annals of medicine · 2026Review
- Cardiovascular Nanomedicine: Breakthroughs in Therapy-Challenges in Safety and Cardiotoxic Risks: A Comprehensive Review of Inorganic Nanoparticles.Cardiovascular toxicology · 2026Review
- Nanomedicine in Cardiovascular Inflammation: Novel Diagnostic and Therapeutic Strategies.Journal of personalized medicine · 2026Review
- From targeted delivery to inflammation suppression: engineering plant exosomes for heart failure therapy post-infarction.Materials today. Bio · 2026Article
- Zebrafish as a Model for Cardiovascular Disease Using Nanotechnology and Emerging Optogenetic Tools.Biomedicines · 2026Review
- Cancer treatment-related cardiotoxicity, molecular mechanism, challenges, and research trends.Discover oncology · 2026Review
- Artificial intelligence-driven design and optimization of mitochondria-targeted nanocarriers for chronic heart failure.Frontiers in bioengineering and biotechnology · 2026Review
- A comprehensive review of ischemic heart disease: pathophysiology, current treatments, natural products-based therapies, and nanotherapeutics.Frontiers in pharmacology · 2026Review
- Application Prospects of Nanotechnology in the Diagnosis and Treatment of Cardiovascular Diseases.International journal of nanomedicine · 2026Review
- Corvad as a bridge to LVAD implantation in end-stage heart disease complicated by cardiogenic shock: a three-case series.Frontiers in cardiovascular medicine · 2026Article
- The Heart-Brain Axis in the Artificial Intelligence Era: Integrating Old and New Insights Towards New Targeting and Innovative Neuro- and Cardio-Therapeutics.International journal of molecular sciences · 2025Review
- Revamping Parkinson's disease therapy using PLGA-based drug delivery systems.NPJ Parkinson's disease · 2025Review
- Reprogramming Atherosclerosis: Precision Drug Delivery, Nanomedicine, and Immune-Targeted Therapies for Cardiovascular Risk Reduction.Pharmaceutics · 2025Review
- Cell Reprogramming, Transdifferentiation, and Dedifferentiation Approaches for Heart Repair.International journal of molecular sciences · 2025Review
- Advanced passive 3D bioelectronics: powerful tool for the cardiac electrophysiology investigation.Microsystems & nanoengineering · 2025Review
- The Application and Molecular Mechanisms of Mitochondria-Targeted Antioxidants in Chemotherapy-Induced Cardiac Injury.Current issues in molecular biology · 2025Review
- Stimuli-responsive Nano/Biomaterials for Smart Drug Delivery in Cardiovascular Diseases: Promises, Challenges and Outlooks.Current medicinal chemistry · 2025Review
- Recent Advances in Aptamers-Based Nanosystems for Diagnosis and Therapy of Cardiovascular Diseases: An Updated Review.International journal of nanomedicine · 2025Review
- Targeting Reactive Oxygen Species for Diagnosis of Various Diseases.Journal of functional biomaterials · 2024Review
- Recent Insights into Endogenous Mammalian Cardiac Regeneration Post-Myocardial Infarction.International journal of molecular sciences · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular diseases (CVDs) remain a leading cause of morbidity and mortality globally. Despite significant advancements in the development of pharmacological therapies, the challenges of targeted drug delivery to the cardiovascular system persist. Innovative drug-delivery systems have been developed to address these challenges and improve therapeutic outcomes in CVDs. This comprehensive review examines various drug delivery strategies and their efficacy in addressing CVDs. Polymeric nanoparticles, liposomes, microparticles, and dendrimers are among the drug-delivery systems investigated in preclinical and clinical studies. Specific strategies for targeted drug delivery, such as magnetic nanoparticles and porous stent surfaces, are also discussed. This review highlights the potential of innovative drug-delivery systems as effective strategies for the treatment of CVDs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.